Obesity-Linked Gastric Cancer: A Converging Epidemic with Surgical Consequences

Research published in the European Journal of Surgical Oncology has highlighted the growing connection between obesity and gastric cancer. According to the study, obesity is now recognized as a carcinogen, promoting tumourigenesis through endocrine, inflammatory, and mechanical pathways. This association has significant implications for gastrointestinal surgical oncology, increasing cancer incidence, stage at diagnosis, and worse oncological outcomes. Experts stress that addressing obesity is crucial not only as a comorbidity but as a modifiable risk factor and therapeutic target across the cancer continuum.

Key Takeaways:

• Obesity is recognized as a carcinogen with significant implications for gastrointestinal surgical oncology, increasing cancer incidence, stage at diagnosis, and worse oncological outcomes.
• Excess adiposity promotes tumourigenesis through endocrine, inflammatory, and mechanical pathways.
• Bariatric surgery and GLP-1 receptor agonists are effective interventions for obesity, but their integration into cancer care remains limited.
• Emerging evidence suggests potential oncological benefit from pharmacological strategies during neoadjuvant pathways, but high-quality data are scarce.
• Routine preoperative obesity screening and referral for structured weight loss should be embedded into multidisciplinary workflows.
• The concept of "obesity as a carcinogen" underscores the importance of addressing this modifiable risk factor in cancer care.
• Joseph Jaya, Joseph Jaya, Rathin Gosavi, Raymond Yap, Vignesh Narasimhan, and Geraldine Ooi are among the researchers who contributed to this study.

Statistics:

• Obesity prevalence is increasing, with significant implications for gastrointestinal surgical oncology.
• Tumourigenesis is promoted through endocrine, inflammatory, and mechanical pathways in obese individuals.
• Bariatric surgery and GLP-1 receptor agonists have shown promising results in reducing obesity, but high-quality data on their integration with cancer care are scarce.
• Perioperative morbidity and mortality associated with obesity in gastrointestinal cancer surgery are significant concerns.
• Randomized trials evaluating short-course pharmacological strategies during neoadjuvant pathways are urgently needed to address these concerns.

Sources:

• NewsRx. New Gastric Cancer Study Findings Reported from Monash Health (Obesity and gastrointestinal cancer: A converging epidemic with surgical consequence). Cancer Weekly. September 2, 2025; p 738.
• European Journal of Surgical Oncology. Obesity and gastrointestinal cancer: A converging epidemic with surgical consequence. 2025;51(10):110358.